CHMP recommends Briumvi to treat relapsing forms of multiple sclerosis.- Propharma Group The Netherlands B.V. + TG Therapeutics
Briumvi will be available as a 150 mg concentrate for solution for infusion. The active substance of Briumvi is ublituximab, a selective immunosuppressant (ATC code: L04AG14) that selectively targets CD20-expressing B-cells involved in the inflammatory changes in the central nervous system of patients with multiple sclerosis.
The benefits of Briumvi are a 49-59% reduction in the annual relapse rate and a greater than 90% reduction in the number of acute inflammatory lesions (97% of Gd-enhancing T1 lesions and 90-92% T2 hyperintense lesions per MRI scan), compared with teriflunomide in two Phase III, randomised, double-blind, active-controlled clinical trials in patients with relapsing multiple sclerosis. The most common side effects are infusion-related reactions and infections.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins